ГЕНОМНАЯ МЕДИЦИНА И ПЕРСОНАЛИЗИРОВАННАЯ ТЕРАПИЯ СЕПСИСА
Аннотация
Обзор литературы посвящен одной из актуальных проблем современной интенсивной терапии – персонализированной терапии сепсиса. Приведено современное определение понятия геномики, и проведен анализ имеющихся по данной проблеме данных, обсуждены преимущества и недостатки такого подхода в интенсивной терапии. Особое внимание уделено перспективам использования генетических биомаркеров в оценке тяжести состояния и прогноза исхода при сепсисе.
Об авторах
П. И. Миронов
ГБОУ ВПО «Башкирский государственный медицинский университет» МЗ РФ, г. Уфа
Россия
доктор медицинских наук, профессор кафедры детской хирургии с курсом ИДПО
Россия
доктор медицинских наук, профессор кафедры детской хирургии с курсом ИДПО
А. У. Лекманов
НИИ хирургии детского возраста ФГБОУ ВПО «РНИМУ им. Н. И. Пирогова» МЗ РФ, Москва
Россия
доктор медицинских наук, профессор, главный научный сотрудник
Россия
доктор медицинских наук, профессор, главный научный сотрудник
Список литературы
1. Abraham E. New definitions for sepsis and septic shock: continuing evolution but with much still to be done // JAMA. – 2016. – Vol. 315. – P. 757–759.
2. Almansa R., Heredia-Rodríguez M., Gomez-Sanchez E. et al. Transcriptomic correlates of organ failure extent in sepsis // J. Infect. – 2015. – Vol. 70, № 4. – P. 445–456.
3. Bagshaw S. M., McDermid R. C. The role of frailty in outcomes from critical illness // Curr. Opin. Crit. Care. – 2013. – Vol. 19, № 5. – Р. 496–503.
4. Bermejo-Martin J. F., Tamayo E., Andaluz-Ojeda D. et al. Characterising Systemic Immune Dysfunction Syndrome (SIDS) to fill in the gaps of SEPSIS-2 and SEPSIS-3 definitions // Chest 2017(Accepted).
5. Buchman T. G., Billiar T. R., Elster E. et al. Precision medicine for critical illness and injury // Crit. Care Med. – 2016. – Vol. 44. – P. 1635–1638.
6. Chan I. S., Ginsburg G. S. Personalized medicine: progress and promise // Ann. Rev. Genomics Hum. Genet. – 2011. – Vol. 12. – P. 217–244.
7. Cohen J., Vincent J. L., Adhikari N. K. et al. Sepsis: A roadmap for future research // Lancet Infect. Dis. – 2015. – Vol. 15. – P. 581–614.
8. Collins F. S., Varmus H. A new initiative on precision medicine // New Engl. J. Med. – 2015. – Vol. 372. – P. 793–795.
9. Cong L., Ran F. A., Cox D. et al. Multiplex genome engineering using CRISPR/Cas systems // Science. – 2013.–Vol. 339. – P. 819–823.
10. Cuenca A. G., Gentile L. F., Lopez M. C. et al. Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients // Crit. Care Med. – 2013. – Vol. 41, № 5. – P. 1175–1185.
11. Davenport E. E., Burnham K. L., Radhakrishnan J. et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study // Lancet Respir. Med. – 2016. – Vol. 4, № 4. – P. 259–271.
12. Delano M. J., Ward P. A. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? // J. Clin. Invest. – 2016. – Vol. 126, № 1. – P. 23–31.
13. Ferrer R., Martin-Loeches I., Phillips G. et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program // Crit. Care Med. – 2014. – Vol. 42. – P. 1749–1755.
14. Gaj T., Gersbach Ch. A., Barbas C. F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering // Trends in Biotechnology. – 2013. – Vol. 31, № 7. – P. 397–404.
15. Gattinoi L., Tonetti T., Quintel M. Improved survival in critically ill patients: are large RCTs more useful then personalized medicine? We are not shure // Intens. Care Med. – 2016. – Vol. 42, № 11. – P. 1781–1783.
16. Goodman D. M., Livingston E. H. Genomic Medicine // JAMA. – 2013. – Vol. 309, № 14. – P. 1544.
17. Knaus W. A., Zimmerman J. E., Wagner D. P. et al. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system // Crit. Care Med. – 1981.– Vol. 9, № 8. – P. 591–597.
18. Knox D. B., Lanspa M. J., Kuttler K. G. et al. Phenotypic clusters within sepsisassociated multiple organ dysfunction syndrome // Intens. Care Med. – 2015. – Vol. 41. – P. 814–822.
19. Lander E. S., Linton L. M., Birren B. et al. Initial sequencing and analysis of the human genome // Nature – 2001. – Vol. 409. – P. 860–921.
20. Laxminarayan R., Duse A., Wattal C. et al: Antibiotic resistance-the need for global solutions // Lancet Infect. Dis. – 2013. – Vol. 13. – P. 1057–1058.
21. Leentjens J., Kox M., van der Hoeven J. G. et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? // Am. J. Respir. Crit. Care Med. – 2013. – Vol. 187, № 12. – P. 1287–1293.
22. Li R., Fang L., Tan Sh. Type I CRISPR-Cas targets endogenous genes and regulates virulence to evade mammalian host immunity // Cell. Research. – 2016. – Vol. 26. – P. 1273–1287.
23. Liang P., Xu Y., Zhang X. et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes // Protein Cell. – 2015. – Vol. 6, № 5.– P. 363–372.
24. Maslove D. M., Wong H. R. Gene expression profiling in sepsis: timing, tissue, and translational considerations // Trends Mol. Med. – 2014. – Vol. 20. – P. 204–213.
25. Maslove D. M., Lamontagne F., Marshall J. C. et al. A path to precision in the ICU // Crit. Care. – 2017. – Vol. 21:79. DOI 10.1186/s13054–017–1653–x.
26. Mathias B., Lipori G., Lyle L. et al. Integrating «big data» into surgical practice // Surgery. – 2016. – Vol. 159. – P. 371–374.
27. Opal S. M., Dellinger R. P., Vincent J. L. et al. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? // Crit. Care Med. – 2014. – Vol. 42. – P. 1714–1721.
28. Parnell G., McLean A., Booth D. et al. Aberrant cell cycle and apoptotic changes characterise severe influenza A infection – a meta-analysis of genomic signatures in circulating leukocytes // PLoS One – 2011. – Vol. 6. – Р. e17186.
29. Parnell G. P.,Tang B. M., Nalos M. et al. Identifying key regulatory genes in the whole blood of septic patients to monitor underlying immune dysfunctions // Shock. – 2013. – Vol. 40, № 3. – P. 166–174.
30. Peltonen L., McKusick V. A. Dissecting human disease in the postgenomic era // Science. – 2001. – Vol. 291. – P. 1224–1229.
31. Prescott H. C., Calfee C. S., Thompson B. T. et al. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design // Am. J. Respir. Crit. Care Med. – 2016. – Vol. 194. – P. 147–155.
32. Puthucheary Z. A., Wischmeyer P. Predicting critical illness mortality and personalizing therapy: moving to multidimensional data // Crit. Care. – 2017. – Vol. 21. – 20 DOI 10.1186/s13054–016–1597–6
33. Rello J., Valenzuela-Sánchez F. Septic shock in the era of precision medicine // J. Thorac Dis. – 2016. – Vol. 8. – P. 1022–1023.
34. Russell J. A. Genomics and pharmacogenomics of sepsis: so close and yet so far // Crit. Care. – 2016. – Vol. 42. – P. 1–4.
35. Shankar-Hari M. et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3) // JAMA. – 2016. – Vol. 315. – P. 775–787.
36. Simpson S. O. New sepsis criteria: a change we should not make // Chest. – 2016. – Vol. 149, № 5. – Р. 1117–1118.
37. Sims C. R., Nguyen T. C., Mayeux P. R. Could biomarker direct therapy for the septic patients? // J. Pharmacol. Exp. Ther. – 2016. – Vol. 357, № 2. – P. 228–239.
38. Singer M., Deutschman C. S., Seymour C. W. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3) // JAMA. – 2016. – Vol. 315. – P. 801–810.
39. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016 // Crit. Care Med. – 2017. – Vol. 45, № 3. – P. 486–552.
40. Sweeney T. E., Wong H. R. Risk stratification and prognosis in sepsis: what have we learned from microarrays? // Clin. Chest Med. – 2016. – Vol. 37. – P. 209–218.
41. Sweeney T. E., Khatri P. Benchmarking sepsis gene expression diagnostics using public data // Crit. Care Med. – 2017. – Vol. 45. – P. 1–10.
42. Sweeney T. E., Perumal T. M., Henao R. et al. Mortality prediction in sepsis via gene expression analysis: a community approach. bioRxiv. preprint first posted online Dec. 19, 2016; doi: http://dx.doi.org/10.1101/095489
43. Tang В. М. Р., McLean A. S., Dawes I. W. et al. Gene-expression profiling in sepsis diagnosis // Am. J. Respir. Crit. Care Med. – 2007. – Vol. 176. – P. 676–684.
44. Tsalik E. L., Langley R. J., Dinwiddie D. L. et al. An integrated transcriptome and expressed variant analysis of sepsis survival and death // Genome Med. – 2014. – Vol. 6, № 11. – P. 111.
45. Wong H. R., Shanley T. P., Sakthivel B. et al. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome // Physiol. Genomics. – 2007. – Vol. 30, № 2. – P. 146–155.
46. Wong H. R., Cvijanovich N. Z., Anas N. et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock // Am. J. Respir. Crit. Care Med. – 2015. – Vol. 191, № 3. – P. 309–315.
47. Wong H. R., Weiss S. L., Giuliano Jr. J. S. et al. Testing the Prognostic Accuracy of the Updated Pediatric Sepsis Biomarker Risk Model // PLoS ONE. – 2016. – Vol. 9, № 1. – Р. e86242.
48. Wong H. R., Cvijanovich N. Z., Anas N. et al. Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers: PERSEVERE–XP // Am. J. Resp. Crit. Care Med. – 2017 Accepted: March 20, 2017 DOI: http://dx.doi.org/10.1164/rccm.201701–0066OC
49. Vogel and Motulski’s Human Genetics: Problems and Approaches. Springer, 2009.
Рецензия
Для цитирования:
Миронов П.И., Лекманов А.У. ГЕНОМНАЯ МЕДИЦИНА И ПЕРСОНАЛИЗИРОВАННАЯ ТЕРАПИЯ СЕПСИСА. Вестник анестезиологии и реаниматологии. 2017;14(3):35-43. https://doi.org/10.21292/2078-5658-2017-14-3-35-43
For citation:
Mironov P.I., Lekmanov A.U. GENOMIC MEDICINE AND PERSONALIZED MANAGEMENT OF SEPSIS. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2017;14(3):35-43. (In Russ.) https://doi.org/10.21292/2078-5658-2017-14-3-35-43
Просмотров: 553
Послать статью по эл. почте 
